Brenner v. Manson
Patent ruling lets the Supreme Court review patent appeals from the specialized patent court and restricts process patents when the chemical made has no demonstrated practical use, making it harder to patent research-only processes.
Holding
The Court held that it may review patent appeals from the Court of Customs and Patent Appeals by certiorari and reversed that court, ruling a chemical process patent requires a demonstrated specific utility for its product.
Real-world impact
- Allows Supreme Court review of decisions from the patent appeals court.
- Makes it harder to patent processes that yield compounds with no proven practical use.
- Requires applicants to show specific, demonstrated utility for compounds before granting process patents.
Topics
Summary
Background
A chemist, Mr. Manson, sought a patent for a chemical process to make certain known steroids after two other inventors had earlier filed for the same process. Manson asked for an interference to establish priority, but the Patent Office refused because his application did not show any practical use for the compound produced. The Court of Customs and Patent Appeals reversed that refusal, and the Supreme Court agreed to review both the jurisdiction question and the patentability issue.
Reasoning
The Court answered two questions. First, it held that federal law authorizes the Supreme Court to review decisions from the patent appeals court by certiorari, including petitions from the Commissioner of Patents. Second, on the patent issue the Court reversed the appeals court: a chemical process patent must be tied to a demonstrated, specific utility of the compound produced. The Court said utility cannot be presumed merely because a related compound is under scientific study or because the process produces the intended product. The Court accepted the Patent Office finding that Manson had not shown a sufficient likelihood of the claimed tumor-inhibiting activity.
Real world impact
The decision limits patents for chemical processes that produce compounds of uncertain or purely investigational value. Chemists and companies will generally need to show a clear, specific practical use for a compound before securing a process monopoly. The ruling also confirms that the Supreme Court can review the patent appeals court’s decisions.
Dissents or concurrances
Justice Harlan disagreed on the patent policy point, arguing that process patents that advance research should be patentable and that historical practice favored broader protection; Justice Douglas concurred in the jurisdiction ruling.
Opinions in this case
- 1.Opinion 107190
- 2.Opinion 9423185
- 3.Opinion 9423186
Questions, answered
Ask questions about the entire case, including all opinions (majority, concurrences, dissents). Try:
- “What was the Court's main decision and reasoning?”
- “How did the dissenting opinions differ from the majority?”
- “What are the practical implications of this ruling?”